SHANGHAI – During the ChinaTrials meeting in Shanghai last week it was clear that many China biopharmas view entering the U.S. market as necessary for long-term success. When looking ahead, they lack confidence the China market will sufficiently reward investments in new drugs. Even after sweeping regulatory reforms have been made in biopharma’s favor, reimbursement remains an issue.